Zymeworks Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company with common stock trading under ZYME. Recent Form 8-K reports cover operating results and financial condition, Regulation FD disclosures, executive appointments, board changes, share repurchase authorization and material agreements involving royalty interests tied to Ziihera (zanidatamab-hrii).
The filing record also includes proxy materials for annual meeting matters, including stockholder voting procedures, governance disclosures and executive compensation. These filings describe Zymeworks' licensed healthcare assets, collaboration and royalty arrangements, capital allocation actions and public-company governance structure.
Schneider Paul R reported acquisition or exercise transactions in this Form 4 filing.
Zymeworks Inc. reported that EVP and General Counsel Paul R. Schneider received new equity compensation. On May 13, 2026, he was granted 119,000 restricted stock units, each representing one share of common stock upon vesting, and 178,000 stock options with a strike price of $24.57 per share.
The options vest 25% on the first anniversary of the grant and the remaining 75% in 36 equal monthly installments. The RSUs vest in four equal annual installments beginning on the first anniversary of the grant date. Following these awards, he holds 119,000 RSUs and 178,000 options directly.
Zymeworks Inc. executive vice president and general counsel Paul R. Schneider filed an initial Form 3 indicating he currently has no securities beneficially owned in the company. The filing lists holding entries showing zero shares and no derivative securities, so it reflects a baseline ownership position of none.
Zymeworks Inc. Schedule 13G/A filing: Rubric Capital Management and David Rosen report beneficial ownership of 7,000,000 shares of Zymeworks common stock, representing 9.49% of the class based on 73,749,607 shares outstanding as of February 6, 2026. The shares are held by Rubric Funds, including Rubric Capital Master Fund LP, which has voting and dispositive power shared among the Reporting Persons.
Zymeworks Inc. has authorized a new 2026 share repurchase program allowing it to buy back up to $125.0 million of its common stock. The Board terminated the prior 2025 program, under which Zymeworks repurchased 4,197,553 shares at an average price of $24.36, totaling $102.3 million. As of May 13, 2026, the company had about 73.0 million common shares outstanding. Zymeworks states that, based on current plans and assuming full execution of the new program, existing cash as of March 31, 2026 plus anticipated regulatory milestone payments of $440.0 million related to potential Ziihera approvals are expected to fund operations beyond 2028.
Zymeworks Inc. reported a first-quarter 2026 net loss of $44.2 million, wider than the prior year, as collaboration revenue fell to $2.4 million from milestone-heavy Q1 2025. Operating expenses were stable at $49.5 million, with research and development of $34.5 million and general and administrative of $15.1 million.
Cash, cash equivalents and marketable securities rose to $403.8 million as of March 31, 2026, helped by a $250.0 million non‑recourse term loan obtained through monetizing 30% of future Ziihera royalties, recorded as a $246.5 million liability. The company continued its share repurchase strategy, buying back 3.2 million shares for $76.6 million in the quarter. Zymeworks highlights upcoming regulatory milestones for Ziihera in HER2‑positive gastroesophageal cancers and ongoing development of its ADC and multispecific antibody pipeline.
Zymeworks Inc. reported first quarter 2026 results, with revenue of $2.4 million, down from $27.1 million a year earlier as prior non-recurring clinical milestone payments rolled off and collaboration and royalty revenue became the main drivers.
R&D expense was $34.5 million and G&A was $15.1 million, both slightly lower year over year, leading to a net loss of $44.2 million versus $22.6 million in 2025. Adjusted gross operating expense (non-GAAP) declined to $42.6 million from $46.3 million.
The company ended March 31, 2026 with $403.8 million in cash, cash equivalents and marketable securities and reiterated guidance for approximately $300 million in aggregate adjusted gross operating expenses over 2026–2028. It expects 2026 adjusted gross operating expenses to be about 20% lower than 2025 on a non-GAAP basis.
Zymeworks highlighted regulatory momentum for partnered HER2 antibody Ziihera (zanidatamab-hrii), including U.S. FDA Priority Review for first-line HER2-positive GEA with an August 25, 2026 PDUFA date and sBLA acceptances in China. Potential approval milestones across territories total $440 million.
The company continued to advance wholly owned ADC ZW191, reporting Phase 1 ovarian cancer data with confirmed objective response rates above 50% and high disease control rates, and presented a new RAS inhibitor ADC platform. It also used $95.8 million to repurchase 3.93 million shares under a $125 million buyback, leaving about 73.0 million shares outstanding.
Zymeworks Inc. reports a Schedule 13G filing showing Perceptive-linked holders beneficially own 3,974,579 shares of Common Stock. The filing states this equals 5.4% of the class based on 73,749,607 shares outstanding as of February 26, 2026. Perceptive Life Sciences Master Fund directly holds the shares; Perceptive Advisors and Joseph Edelman are reported as investment manager and managing member, respectively.
Zymeworks Inc. reported that officer Adam Schayowitz received new equity awards as part of his compensation. On April 9, 2026, he was granted stock options for 70,000 shares of common stock at an exercise price of $27.35 per share, expiring on April 8, 2036. These options vest 25% on the first anniversary of the grant and the rest in 36 monthly installments.
He also received 47,000 restricted stock units that vest in four equal annual installments, plus up to 76,000 performance stock units. The performance units can be earned between 50% and 200% of a 38,000-unit target based on cumulative total shareholder return over a three-year period ending on January 12, 2029, subject to continued service and specific TSR goals.
Zymeworks Inc. granted equity-based compensation to EVP and Chief Business Officer Scott Platshon. He received stock options for 70,000 shares of common stock at an exercise price of $27.35 per share, expiring on April 8, 2036, which vest 25% after one year and monthly thereafter.
Platshon was also granted 47,000 restricted stock units that vest in four equal annual installments, each RSU delivering one share of common stock upon vesting. In addition, he received 76,000 performance stock units, representing the maximum number that may be earned based on cumulative total shareholder return goals over a three-year performance period ending on January 12, 2029, with 50%–200% of a 38,000-unit target earnable depending on performance.
Zymeworks Inc. disclosed initial equity holdings for executive Adam Schayowitz. He holds stock options covering 167,000 shares of common stock with an exercise price of $16.92 per share, expiring on October 8, 2035. These options were granted on October 9, 2025 and vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Schayowitz also holds 111,111 restricted stock units (RSUs) granted on October 9, 2025. These RSUs vest in three equal annual installments beginning October 9, 2026. Each RSU represents the contingent right to receive one share of Zymeworks common stock upon vesting.